REG - Abingdon Health PLC - Result of Retail Offer

Abingdon HealthAnnouncement

17/10/2025 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20251017:nRSQ7494Da&default-theme=true

RNS Number : 7494D  Abingdon Health PLC  17 October 2025

THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED HEREIN ARE RESTRICTED AND ARE
NOT FOR PUBLICATION, RELEASE OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR
INTO OR FROM THE UNITED STATES, AUSTRALIA, CANADA, JAPAN, THE REPUBLIC OF
SOUTH AFRICA OR ANY JURISDICTION IN WHICH THE SAME WOULD BE UNLAWFUL.

 

THIS ANNOUNCEMENT IS FOR INFORMATION PURPOSES ONLY AND DOES NOT CONSTITUTE AN
OFFER TO SELL OR ISSUE OR A SOLICITATION TO BUY, SUBSCRIBE FOR OR OTHERWISE
ACQUIRE ANY SECURITIES IN ANY JURISDICTION IN WHICH ANY SUCH OFFER OR
SOLICITATION WOULD BE UNLAWFUL, INCLUDING THE UNITED STATES, CANADA,
AUSTRALIA, JAPAN OR THE REPUBLIC OF SOUTH AFRICA. NEITHER THIS ANNOUNCEMENT
NOR ANYTHING CONTAINED HEREIN SHALL FORM THE BASIS OF, OR BE RELIED UPON IN
CONNECTION WITH, ANY SUCH OFFER, SOLICITATION OR COMMITMENT WHATSOEVER IN ANY
OF THOSE JURISDICTIONS.

 

TERMS NOT OTHERWISE DEFINED HEREIN SHALL HAVE THE MEANINGS GIVEN TO THEM IN
THE COMPANY'S ANNOUNCEMENT RELEASED ON 13 OCTOBER 2025 AT 5:04PM.

 

 

 

17 October 2025

Abingdon Health plc

 

("Abingdon Health", the "Group" or the "Company")

 

Result of Retail Offer

 

Abingdon Health plc (AIM: ABDX), a leading international developer,
manufacturer and regulatory services provider for rapid diagnostic tests and
med-tech, announces that the Retail Offer launched on 14 October 2025 via the
bookbuild platform has raised in aggregate £176,509.26 through the issuance
of 2,941,821 Retail Offer Shares at a price of 6 pence per share.

 

Accordingly, the Company has conditionally raised total gross proceeds of
approximately £3.4 million in aggregate by way of the Placing and Retail
Offer.

 

A separate announcement will be made following the General Meeting as to the
results of the General Meeting and the total voting rights following
Admission.

 

Admission

 

Application will be made to the London Stock Exchange for admission of the New
Ordinary Shares to trading on AIM. It is expected that, subject to the
necessary resolutions being passed at the General Meeting, Admission will
become effective and dealings in the new Ordinary Shares will commence at 8:00
a.m. on 31 October 2025. The new Ordinary Shares will be issued fully paid and
will rank pari passu in all respects with the Company's Existing Ordinary
Shares.

 

Admission is conditional, inter alia, upon Admission becoming effective, the
Placing Agreement not having been terminated and becoming unconditional, and
upon the approval of the Resolutions by the Shareholders at the Company's
forthcoming General Meeting to be held on 30 October 2025.

 

Capitalised terms used but not defined in this announcement have the meanings
given to them in the Company's announcement released at 5:04 p.m. on 13
October 2025 in respect of the Proposed Placing to raise up to £3.34 million
(before expenses) and Retail Offer to raise up to £200,000 (before expenses)
unless the context provides otherwise.

 

Enquiries:

 Abingdon Health plc                           www.abingdonhealth.com/investors/ (http://www.abingdonhealth.com/investors/)
 Chris Hand, Executive Chairman                                            Via Walbrook PR

 Tom Hayes, Chief Financial Officer

 Zeus (Sole Broker and Nominated Adviser)                                    Tel: +44 (0)20 3829 5000
 Antonio Bossi / Darshan Patel / Jacob Walker (Corporate Finance)
 Nick Searle / Fraser Marshall (Corporate Broking)

 Walbrook PR (Media & Investor Relations)      Tel: +44 (0)20 7933 8780 or abingdon@walbrookpr.com
                                               (mailto:abingdon@walbrookpr.com)
 Paul McManus / Alice Woodings                 Mob: +44 (0)7980 541 893 / +44 (0)7407 804 654

 

 

About Abingdon Health plc

Abingdon Health Group is a leading med-tech contract service provider
offering its services to an international customer base.

 

The Group's CDMO
(https://www.abingdonhealth.com/services/your-complete-lateral-flow-partner/)
expertise offers lateral flow product development, regulatory support,
technology transfer and manufacturing services for customers looking to
develop new assays or transfer existing laboratory-based assays to a lateral
flow format.  Abingdon Health has the internal capabilities to take lateral
flow projects, in areas such as infectious disease and clinical testing,
including companion diagnostics, animal health and environmental testing, from
initial concept through to routine manufacturing; from "idea to commercial
success".  Abingdon Analytical Ltd offers performance evaluation for lateral
flow and other in vitro diagnostic assays from its Doncaster laboratory.

 

Founded in 2008, Abingdon Health is headquartered in York, England with
laboratories in Doncaster, England and laboratories and commercial offices in
Madison, Wisconsin, USA.

 

Abingdon Health's brochure
(https://www.abingdonhealth.com/wp-content/uploads/2025/06/Abingdon-Health-Group-Leaflet-JUN2025.pdf)
 outlines the comprehensive support the Group can now provide to its
international customers.  For more information visit: www.abingdonhealth.com
(https://urldefense.proofpoint.com/v2/url?u=http-3A__www.abingdonhealth.com_&d=DwMFAg&c=euGZstcaTDllvimEN8b7jXrwqOf-v5A_CdpgnVfiiMM&r=b40MoFA_Q_fdsT77LXB5t3JFUZjlmpd2MVbmgvoBIOo&m=5rmPWmSeAYNtvo-wVGL_4V7p0wZ2qRPhbqDj6E6FHnhVakMVyzvk7wZG1jS6vI4P&s=Cd1Yy0EoU5vx33xedoTE3bCKbljgDOIRD8ol-bb59BM&e=)
.

 

The Company's LEI is 213800XFI4WV3FBILO20.

 

This announcement should be read in its entirety. In particular, the
information in the "Important Notices" section of the announcement should be
read and understood.

 

Important Notices

 

The content of this announcement has been prepared by and is the sole
responsibility of the Company.

This announcement and the information contained herein is not for release,
publication or distribution, directly or indirectly, in whole or in part, in
or into or from the United States (including its territories and possessions,
any state of the United States and the District of Columbia, Australia,
Canada, Japan, the Republic of South Africa, any member state of the EEA or
any other jurisdiction where to do so might constitute a violation of the
relevant laws or regulations of such jurisdiction.

The distribution of this announcement may be restricted by law in certain
jurisdictions and persons into whose possession any document or other
information referred to herein comes should inform themselves about and
observe any such restriction. Any failure to comply with these restrictions
may constitute a violation of the securities laws of any such jurisdiction.

Zeus Capital Limited ("Zeus") is authorised and regulated in the United
Kingdom by the FCA, is acting exclusively for the Company and for no-one else
and will not regard any other person (whether or not a recipient of this
announcement) as its client in relation to the transactions and arrangements
described in this announcement and will not be responsible to anyone other
than the Company for providing the protections afforded to its clients, nor
for providing advice in connection with the contents of this announcement, or
the transactions, referred to in this announcement.

The value of Ordinary Shares and the income from them is not guaranteed and
can fall as well as rise due to stock market and currency movements. When you
sell your investment, you may get back less than you originally invested.
Figures refer to past performance and past performance is not a reliable
indicator of future results. Returns may increase or decrease as a result of
currency fluctuations.

Neither the content of the Company's website (or any other website) nor the
content of any website accessible from hyperlinks on the Company's website (or
any other website) is incorporated into or forms part of this announcement.

The Retail Offer Shares to be issued or sold pursuant to the Retail Offer will
not be admitted to trading on any stock exchange other than AIM.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  ROIUNRKRVBURAAA



            Copyright 2019 Regulatory News Service, all rights reserved